RGS.AX - Regeneus Ltd

ASX - ASX Delayed price. Currency in AUD
0.0800
0.0000 (0.00%)
At close: 12:31PM AEST
Stock chart is not supported by your current browser
Previous close0.0800
Open0.0840
Bid0.0750 x 0
Ask0.0770 x 0
Day's range0.0800 - 0.0840
52-week range0.0490 - 0.1150
Volume68,757
Avg. volume128,198
Market cap22.226M
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date31 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.70
  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Kyocera completes Progenza Due Diligence

    Sydney, Australia, May 18, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Quarterly Report

    Sydney, Australia, April 29, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities ...

  • If You Had Bought Regeneus (ASX:RGS) Stock Five Years Ago, You'd Be Sitting On A 54% Loss, Today
    Simply Wall St.

    If You Had Bought Regeneus (ASX:RGS) Stock Five Years Ago, You'd Be Sitting On A 54% Loss, Today

    Regeneus Ltd (ASX:RGS) shareholders should be happy to see the share price up 30% in the last month. But that can't...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) to be granted new key Progenza patent in U.S.

    Sydney, Australia, Mar 23, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Receives A$1.6M Milestone Payment from Kyocera

    Sydney, Australia, Mar 20, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Signs MOU with Kyocera Corporation

    Sydney, Australia, Mar 2, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Half-Year Results & Business Update

    Sydney, Australia, Feb 28, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS.AX - News) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Directors Provide $4m Loan Facility

    Sydney, Australia, Feb 28, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announced its Board of Directors has put in place ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly

    Sydney, Australia, Jan 31, 2020 - (ABN Newswire) - Regeneus Ltd (ASX:RGS.AX - News) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20). During the quarter, the Company and AGC terminated their exclusive manufacturing licence and joint venture agreement, a mutual decision which provides Regeneus with the flexibility to conclude commercial licence discussions with partners who intend to manufacture and commercialise Progenza OA in Japan. Following termination, AGC is entitled to be issued with 22,794,531 ordinary shares in Regeneus.

  • Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) AGC Agreement Termination Paves Way for Commercial Partner

    Sydney, Australia, Dec 20, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS.AX - News) (Regeneus or the Company), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc (AGC) to terminate their exclusive manufacturing licence and joint venture agreement (refer to ASX announcement dated 29 December 2016). Regeneus and AGC have successfully achieved the intent of the original agreement in which Regeneus transferred its cellular therapy manufacturing know-how to AGC and AGC lead the identification and introduction of potential commercial partners in Japan.

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Receives Innovation Grant

    Sydney, Australia, Dec 18, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) ("Regeneus" or "the Company"), a clinical-stage regenerative medicine company, has received $50K in funding ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO AGM Presentation

    Sydney, Australia, Nov 21, 2019 - (ABN Newswire) - 2019 was a productive year as we continued our aim of commercialising Progenza and Sygenus, our core regenerative medicine technology platforms. In particular, our focus has been on the lead platform, Progenza, which has shown positive results for treating osteoarthritis in its Phase 1 trials. The market for osteoarthritis is significant and worth US$9.5bn across Japan, the US and Europe and we believe this represents a significant commercial opportunity for Regeneus.

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Japanese Biotech Fund takes up all Rights Issue Shortfall

    Sydney, Australia, Nov 19, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Annual Report 2019

    Sydney, Australia, Oct 30, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS.AX - News) is a Sydney Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology. During the year, the company secured a number of clinical milestones for their platform technologies.

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Receives A$1.5 million in R&D Tax Incentives

    Sydney, Australia, Oct 15, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received $1.5 million in R&D Tax Incentives from ...

  • ABN Newswire

    Regeneus Ltd (ASX:RGS) Financial Report - Year Ended 30 June 2019

    Sydney, Australia, Sep 26, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its financial results for the financial year ...

  • Before You Buy Regeneus Ltd (ASX:RGS), Consider Its Volatility
    Simply Wall St.

    Before You Buy Regeneus Ltd (ASX:RGS), Consider Its Volatility

    If you own shares in Regeneus Ltd (ASX:RGS) then it's worth thinking about how it contributes to the volatility of...